Remove 2024 Remove Communication Remove Dosage Remove FDA
article thumbnail

Naltrexone interactions to avoid

The Checkup by Singlecare

Food and Drug Administration (FDA) to treat opioid use disorder and alcohol use disorder. Communicating openly with your healthcare team about all medical conditions you have and medications you take is the best way to identify potential naltrexone interactions. It comes as an oral tablet and intramuscular (IM) injection.

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. mL, 3 mg/0.5 Those with Medicare or Medicaid coverage are not eligible.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new.

Dosage 115
article thumbnail

Enabling Global Pharma Innovation: Delivering for Patients

ISPE

In addition, this article provides an explanation of the purpose and expected outcomes from the survey, subsequent plans for communicating the results from the survey across ISPE, and development of concrete proposals to address the sources of challenges and barriers to innovation. 22 June 2023. link] 16 US Food and Drug Administration.

FDA 52
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

Last year, Novartis began with a win in January, as the US Court of Appeals affirmed the validity of Gilenya’s patent, allowing the company to sue a competitor generics company for filing for FDA approval for its Gilenya generic. Gilenya is an oral medication for multiple sclerosis. Fighting Entresto generics.